{
  "publication": {
    "pmc_id": "PMC11929063",
    "title": "Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII",
    "year": "2025",
    "journal": "Mol Ther Methods Clin Dev"
  },
  "authors": [
    "Lengler Johannes",
    "Weiller Markus",
    "Horling Franziska",
    "Mayrhofer Josef",
    "Schuster Maria",
    "Falkner Falko G",
    "Gil-Farina Irene",
    "Klugmann Matthias",
    "Scheiflinger Friedrich",
    "Hoellriegl Werner",
    "Rottensteiner Hanspeter"
  ],
  "subjects": {
    "species": [
      "Mus musculus",
      "C57BL/6J"
    ],
    "tissues": [
      "liver"
    ]
  },
  "methods": {
    "platforms": [
      "immunological tolerance assay",
      "hemostatic efficacy assay",
      "biodistribution assessment",
      "toxicity assessment"
    ],
    "assays": [
      "plasma FVIII activity assay",
      "blood loss assay",
      "FVIII expression assay",
      "vector DNA quantification"
    ]
  },
  "treatments": [
    {
      "agent": "TAK-754",
      "dose": "1.0\u00a0\u00d7\u00a01012 - 5.0\u00a0\u00d7\u00a01013 CP/kg",
      "duration": "single administration"
    }
  ],
  "results": [
    {
      "target": "plasma FVIII activity",
      "effect": "increase",
      "magnitude": "dose-dependent"
    },
    {
      "target": "blood loss",
      "effect": "decrease",
      "magnitude": "dose-dependent"
    },
    {
      "target": "FVIII expression",
      "effect": "long-term and stable",
      "magnitude": "high levels"
    },
    {
      "target": "vector DNA in other tissues",
      "effect": "low occurrence",
      "magnitude": "minimal"
    }
  ]
}